Navigation Links
Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
Date:1/12/2009

Adverse Cardiovascular Events (MACE) over the duration of the trial. In this study, MACE is defined as a composite endpoint consisting of cardiovascular death, non-fatal stroke, non-fatal myocardial infarction, unstable angina, and a subset of revascularization following the initial event. During the course of the study, patients will receive therapeutic standard of care in addition to high dose Lipitor(R) (atorvastatin). In previous clinical trials, varespladib, a potent and highly selective inhibitor of secretory phospholipase A2 (sPLA2), has demonstrated marked improvements in independent markers of cardiovascular risk including a near complete suppression of the target enzyme sPLA2, a clinically meaningful and statistically significant reduction in "bad" LDL cholesterol, and a reduction in C-reactive protein, a known marker of inflammation.

About Acute Coronary Syndrome

Acute coronary syndrome is a heart condition characterized by chest pain occurring at rest or upon minimal exertion. This condition is also referred to as unstable angina. If the chest pain is associated with heart muscle damage and heart tracing abnormalities, it is typically classified as a heart attack or myocardial infarction.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shionogi & Co.┬┐ Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family - a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes┬┐ prostacyclins and other mediators of in
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Anthera Pharmaceuticals Forms Scientific Advisory Board
3. Anthera Presents Data on Varespladib at ATVB Meeting
4. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
5. Antheras Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease
6. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
7. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Carrington Completes $8 Million Financing
10. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
11. New Brunswick Scientific Completes Merger Transaction with Eppendorf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  Asterias Biotherapeutics, Inc. (OTCBB: ... field of regenerative medicine, announced today that it ... to investors on Tuesday, July 29, 2014, at ... will include an overview of Asterias, business strategy ... visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes ...
(Date:7/24/2014)... forces worldwide rely on sophisticated equipment, trained personnel, ... public areas against terrorist attacks. A revolutionary new ... to make their job much easier. , The ... of Tel Aviv University ,s School of Chemistry ... by the Herzliya company Tracense, picks up the ...
(Date:7/24/2014)... computers have yet to materialise. Yet, scientists are ... such computers faster. One such approach relies on ... by applying an electric field. A new study ... coupled quantum dots (TQDs) with electrical impulses can ... example, should TQDs be used as quantum information ...
(Date:7/24/2014)... synthetic processes prefer to settle into equilibriuma state ... within the realm of non-equilibrium conditions where new ... energy and phases, such as temperature fluctuations, freezing ... to regulate their body temperature, airplanes to fly, ... , But even though these conditions exist ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Nano-sized chip 'sniffs out' explosives far better than trained dogs 2New approach to form non-equilibrium structures 2
... BASEL, Switzerland, April 17 Syngenta today,announced that it ... in,Beijing, China. Its focus will be on early-stage evaluation ... corn and soy, in the areas of yield,improvement, drought ... facility will have a global scope and will complement,Syngenta,s ...
... NexGenix Pharmaceuticals, presented,data on its Hsp90 inhibitor program ... San Diego today. The company presented data in ... novel, radicicol-based,Hsp90 inhibitors in its compound series., ... models,without evidence for liver and kidney toxicity. The ...
... Offers a Complete Solution for the Study of ... ... (Nasdaq:,SIAL) today announced the launch of its Imprint(TM) Chromatin,Immunoprecipitation Kit ... a complete,solution for Chromatin Immunoprecipitation, including columns and reagents,for DNA ...
Cached Biology Technology:Syngenta To Build Major Global Biotech Research Center in Beijing, China 2Syngenta To Build Major Global Biotech Research Center in Beijing, China 3NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 2NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 3Sigma(R) Launches Innovative ChIP Kit Technology For Epigenetic Research 2Sigma(R) Launches Innovative ChIP Kit Technology For Epigenetic Research 3
(Date:7/24/2014)... how wildlife loss leads to conflict among people around ... Conservation Society (WCS) Health & Ecosystems: Analysis of Linkages ... interdisciplinary approach to tackle global biodiversity decline. , The ... the world,s people and provides protein for more than ... as no surprise that today,s unprecedented loss of wildlife, ...
(Date:7/24/2014)... -- The Geneva Healthcare Suite, an innovative technology platform ... room wait times by an average of 92 minutes ... to a recent study published in the Academic Emergency ... suite to access data from incoming patients, implanted cardiac ... Geneva,s technology platform we have been able to quickly ...
(Date:7/24/2014)... native animal species for food or commercial food sale, ... in the decline of many species of primates and ... more than half of the species being consumed are ... surveying not only the meat made available for sale ... forest by hunters and brought to villages for consumption, ...
Breaking Biology News(10 mins):New study draws links between wildlife loss and social conflicts 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... plants is determined by pigments such as aurones, anthocyanins, ... displayed is dependent not only on the pigment present, ... of metal ions, and pH, among others. Information about ... plant geneticists to engineer new hues, adding to the ...
... hunted to local extinction more than a century ago and ... whales of mainland New Zealand are coming home. A ... that whales from a small surviving population around remote, sub-Antarctic ... mainland. Before the onslaught of 19th century whaling, historical ...
... Mary, University of London, sheds new light on why people ... suffer organ damage in parts of the body which are ... in Nature Immunology *, examines the way certain white ... defend damaged organs against injury or infection. This is ...
Cached Biology News:Engineering blue-hued flowers 2Fighting back from extinction, New Zealand right whale is returning home 2Fighting back from extinction, New Zealand right whale is returning home 3Rogue blood cells may contribute to post-surgery organ damage 2
Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
Request Info...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
Biology Products: